Request that the FDA determine that the drug product, Amantadine Extended-Release Capsules, 274 mg, is suitable for submission as an ANDA
🏛 Food and Drug Administration (FDA)FDA-2025-P-6646
Documents
0
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.